Study summary

The objective of this study was to evaluate the efficacy and safety of enzalutamide treatment in patients with progressive metastatic castration-resistant prostate cancer previously treated with abiraterone acetate.

Additional Study Details

Phase
4
Product
N/A
Product
Enzalutamide
Type
Interventional
Masking
None (Open Label)
Enrollment number
215
Show Additional Study Details

Study documents

Scientific Results Summary
Available Language(s): English
Scientific Results Summary 2
Available Language(s): English

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate Enzalutamide after Abiraterone in Metastatic Castration-Resistant Prostate Cancer? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Withdrawn
    Site DE49013
    Reutlingen, Germany, 72764
    Completed
    Site FR33015
    Angers cedex 02, France, 49055
    Withdrawn
    Site ES34007
    Sevilla, Sevilla, Spain, 41013
    Completed
    Site DE49005
    Nuertingen, Baden-Wuerttemberg, Germany, 72622
    Completed
    Site DE49015
    Bergisch Gladbach, NW, Germany, 51427
    Completed
    Site GB44001
    Sutton, Surrey, United Kingdom, SM2 5PT
    Withdrawn
    Site BE32006
    Turnhout, Belgium, 2300
    Completed
    Site FR33003
    Marseille CEDEX 9, France, 13273
    Completed
    Site BE32004
    Gent, Belgium, 9000
    Completed
    Site FR33009
    Caen Cedex 05, France, 14076
    Completed
    Site GB44002
    Glasgow, United Kingdom, G12 0YN
    Completed
    Site DE49008
    Hamburg, Germany, 22399
    Withdrawn
    Site FR33006
    Lille, France, 59037
    Completed
    Site FR33014
    Le Mans, France, 72015
    Completed
    Site GB44010
    Plymouth, United Kingdom, PL6 8DH
    Completed
    Site DE49001
    Hamburg, Hamburg, Germany, 22081
    Completed
    Site DE49014
    Berlin, Germany, 10247
    Completed
    Site FR33011
    Paris, France, 75005
    Withdrawn
    Site DE49011
    Waldshut-Tiengen, Germany, 79761
    Completed
    Site FR33002
    Nimes, France, 30029
    Completed
    Site DE49007
    Hannover, Germany, 30625
    Completed
    Site ES34004
    Santiago de Compostela, A Coruna, Spain, 15706
    Completed
    Site ES34001
    Madrid, Madrid, Spain, 28007
    Completed
    Site ES34006
    Barcelona, Barcelona, Spain, 08025
    Completed
    Site FR33012
    Villejiuf, France, 94805
    Completed
    Site DE49016
    Duesseldorf, Germany, 40225
    Completed
    Site FR33001
    Paris cedex 15, France, 75908
    Completed
    Site ES34009
    Badalona, Spain, 8916
    Completed
    Site DE49003
    Berlin, Berlin, Germany, 12200
    Completed
    Site BE32002
    Liege, Belgium, 4000
    Completed
    Site ES34003
    Madrid, Madrid, Spain, 28034
    Completed
    Site ES34010
    Madrid, Madrid, Spain, 28044
    Completed
    Site GB44007
    London, United Kingdom, SE1 9RT
    Completed
    Site BE32007
    Hasselt, Belgium, 3500
    Completed
    Site BE32003
    Kortrijk, Belgium, 8500
    Completed
    Site DE49012
    Munster, Germany, 48149
    Completed
    Site FR33008
    Nantes Saint Herblain Cedex, France, 44805
    Completed
    Site FR33005
    Suresnes, France, 92151
    Completed
    Site DE49002
    Heidelberg, Germany, 69120
    Completed
    Site DE49010
    Dresden, Germany, 01307
    Withdrawn
    Site ES34005
    Pamplona, Navarra, Spain, 31008
    Completed
    Site DE49017
    Duisburg, NRW, Germany, 47179
    Completed
    Site DE49004
    Goettingen, Germany, 37075
    Completed
    Site GB44006
    Withington, United Kingdom, M204BX
    Completed
    Site GB44004
    Birmingham, United Kingdom, B15 2TT
    Completed
    Site GB44003
    Northwood, Middlesex, United Kingdom, HA6 2RN
    Completed
    Site FR33013
    Lyon Cedex 3, France, 69003
    Completed
    Site DE49006
    Tubingen, Germany, 72076
    Completed
    Site FR33007
    Rennes, France, 35042
    Completed
    Site FR33010
    Creteil cedex, France, 94010
    Completed
    Site ES34011
    Barcelona, Spain, 08003
    Completed
    Site GB44009
    Brighton, United Kingdom, BN2 5BE
    Completed
    Site ES34002
    Madrid, Madrid, Spain, 28040
    Completed
    Site BE32001
    Brussels, Flemish Brabant, Belgium, 1200
    Completed
    Site ES34008
    Barcelona, Barcelona, Spain, 08035
    Completed
    Site DE49009
    Bonn, Germany, 53111

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    2

    Why are Clinical Trials Important?

    3

    Why Participate in a Clinical Trial?